Cellectis (NASDAQ:CLLS) Price Target Lowered to $5.00 at Barclays

Cellectis (NASDAQ:CLLS) had its price target lowered by Barclays from $7.00 to $5.00 in a research note published on Tuesday morning, Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Separately, StockNews.com began coverage on Cellectis in a report on Tuesday. They set a “sell” rating for the company.

Cellectis Stock Performance

Shares of Cellectis stock opened at $1.80 on Tuesday. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. Cellectis has a 12 month low of $1.75 and a 12 month high of $3.77. The business has a fifty day simple moving average of $2.08 and a 200-day simple moving average of $2.28. The stock has a market cap of $100.05 million, a PE ratio of -1.38 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. During the same quarter in the prior year, the business posted ($0.31) earnings per share. On average, sell-side analysts anticipate that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Long Focus Capital Management LLC boosted its holdings in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after acquiring an additional 12,467 shares in the last quarter. First Affirmative Financial Network acquired a new position in shares of Cellectis during the 3rd quarter valued at about $45,000. Finally, XTX Topco Ltd bought a new position in shares of Cellectis in the 2nd quarter valued at approximately $29,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.